Bioteque (4107) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024, was NT$1,568,328 thousand, up from NT$1,426,284 thousand year-over-year.

• Net income for the nine months was NT$394,033 thousand, an increase from NT$347,365 thousand year-over-year.

• Basic EPS for the nine months was NT$5.69, compared to NT$5.01 for the same period last year.

Financial highlights

• Gross profit margin for the nine months was 43%, up from 41% year-over-year.

• Operating income for the nine months was NT$480,157 thousand, up from NT$413,390 thousand year-over-year.

• Cash and cash equivalents at September 30, 2024, were NT$1,319,102 thousand.

• Total assets stood at NT$4,492,159 thousand, with total equity of NT$3,288,397 thousand as of September 30, 2024.

Outlook and guidance

• Management expects no significant impact from newly adopted or upcoming IFRS amendments.

• The Group continues to monitor the impact of climate change and regulatory changes on its financial position.